BI’s Article search uses Boolean search capabilities. If you are not familiar with these principles, here are some quick tips.
To search specifically for more than one word, put the search term in quotation marks. For example, “workers compensation”. This will limit your search to that combination of words.
To search for a combination of terms, use quotations and the & symbol. For example, “hurricane” & “loss”.
Reprints
Spending on GLP-1 diabetes drugs under Medicare Part D has surged in recent years, according to a KFF analysis, Fierce Healthcare reports. The study found that spending on Novo Nordisk's Ozempic rose from $56.8m in 2018 to $4.6bn in 2022. The report also noted increased spending on other GLP-1 drugs, with total spending on Ozempic, Novo's Rybelsus, and Eli Lilly's Mounjaro reaching $5.7bn in 2022.
1. Hackers leak stolen data from Change Healthcare on dark web
2. UnitedHealth estimates $1.6 billion loss from Change cyberattack
3. UnitedHealth reports significant data breach; personal health info compromised
4. Ex-NBA player Will Bynum sentenced in insurance fraud scandal
5. Illinois House passes governor’s 'Healthcare Protection Act’
6. Analyst says Cigna, Humana share prices could put merger back on the table